A new treatment combination of pembrolizumab and sacituzumab govitecan has shown improved progression-free survival (PFS) in patients with triple-negative breast cancer (TNBC), according to results from the ASCENT-04/KEYNOTE-D19 trial.
Patients with PD-L1-positive locally advanced or metastatic TNBC who received pembrolizumab and sacituzumab govitecan had a 3.4-month improvement in PFS, compared to 7.8 months for those receiving pembrolizumab and chemotherapy alone. The new combination also resulted in an almost twofold longer duration of response.
The treatment was more effective than standard chemotherapy regimens, with fewer adverse events reported. Neutropenia was the most common grade 3 or 4 side effect, occurring in 43% of patients receiving sacituzumab govitecan.
These findings support the use of pembrolizumab and sacituzumab govitecan as a new standard for previously untreated patients with PD-L1-positive TNBC. The combination is expected to improve outcomes and potentially reduce side effects compared to current treatments.
Experts welcome the results, citing the potential for improved patient care and reduced adverse events. With its approval pending, this treatment combination may soon become the new standard of care for patients with advanced TNBC.
Source: https://www.medscape.com/viewarticle/sacituzumab-or-chemo-first-line-tnbc-which-better-2025a1000eqg